Table 1 Patients, tumor, and treatment characteristics of 100 patients who had Oncotype DX recurrence score assessment
Recurrence score risk category | p value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Whole group | Low Risk | Intermediate risk | High risk | ||||||
n | % | n | % | n | % | n | % | ||
All patients | 100 | 100 | 54 | 54 | 34 | 34 | 12 | 12 | |
Age | |||||||||
Age ≤ 50 years | 51 | 51 | 30 | 55.6 | 16 | 47.1 | 5 | 41.7 | 0.583 |
Age > 50 years | 49 | 49 | 24 | 44.4 | 18 | 52.9 | 7 | 58.3 | |
Menopausal status | |||||||||
Premenopausal | 59 | 59 | 35 | 64.8 | 19 | 55.9 | 5 | 41.7 | 0.304 |
Postmenopausal | 41 | 41 | 19 | 35.2 | 15 | 44.1 | 7 | 58.3 | |
Tumor histological grade | |||||||||
Grade 1 | 15 | 15 | 11 | 20.4 | 4 | 11.8 | 0 | 0 | 0.003 |
Grade 2 | 64 | 64 | 32 | 59.3 | 27 | 79.4 | 5 | 41.7 | |
Grade 3 | 17 | 17 | 9 | 16.7 | 2 | 5.9 | 6 | 50 | |
Grade (unknown) | 4 | 4 | 2 | 3.7 | 1 | 2.9 | 1 | 8.3 | |
Ki-67 index | |||||||||
Ki-67 ≤ 15 | 51 | 51 | 37 | 68.5 | 13 | 38.2 | 1 | 8.3 | < 0.001 |
Ki-67 > 15 | 38 | 38 | 11 | 20.4 | 17 | 50 | 10 | 83.3 | |
Ki-67 (unknown) | 11 | 11 | 6 | 11.1 | 4 | 11.8 | 1 | 8.3 | |
Tumor type | |||||||||
IDC | 94 | 94 | 52 | 96.3 | 30 | 88.2 | 12 | 100 | 0.195 |
ILC | 6 | 6 | 2 | 3.7 | 4 | 11.8 | 0 | 0 | |
Primary tumor surgical approach | |||||||||
WLE | 78 | 78 | 39 | 72.2 | 29 | 85.3 | 10 | 83.3 | .316 |
Mastectomy | 22 | 22 | 15 | 27.8 | 5 | 14.7 | 2 | 16.7 | |
Axillary surgical management | |||||||||
SLN | 84 | 84 | 46 | 85.2 | 28 | 82.4 | 10 | 83.3 | 0.938 |
Axillary clearance | 16 | 16 | 8 | 14.8 | 6 | 17.6 | 2 | 16.7 | |
pT stage | |||||||||
pT1 | 39 | 39 | 24 | 44.4 | 13 | 38.2 | 2 | 16.7 | 0.381 |
pT2 | 55 | 55 | 26 | 48.1 | 20 | 58.8 | 9 | 75 | |
pT3 | 6 | 6 | 4 | 7.4 | 1 | 2.9 | 1 | 8.3 | |
pN stage | |||||||||
pN0 | 76 | 76 | 42 | 77.8 | 25 | 73.5 | 9 | 75 | 0.987 |
pN1mic | 10 | 10 | 5 | 9.3 | 4 | 11.8 | 1 | 8.3 | |
pN1 | 14 | 14 | 7 | 13 | 5 | 14.7 | 2 | 16.7 | |
UICC-AJCC TNM stage | |||||||||
Ia | 31 | 31 | 18 | 33.3 | 11 | 32.4 | 2 | 16.7 | 0.719 |
Ib | 3 | 3 | 3 | 5.6 | 0 | 0 | 0 | 0 | |
IIa | 47 | 47 | 24 | 44.4 | 16 | 47.1 | 7 | 58.3 | |
IIb | 16 | 16 | 8 | 14.8 | 6 | 17.6 | 2 | 16.7 | |
IIIa | 3 | 3 | 1 | 1.9 | 1 | 2.9 | 1 | 8.3 | |
Lymphovascular invasion | |||||||||
LVI+ | 17 | 17 | 5 | 9.3 | 10 | 29.4 | 2 | 16.7 | 0.046 |
LVI− | 78 | 78 | 46 | 85.2 | 22 | 64.7 | 10 | 83.3 | |
LVI-unknown | 5 | 5 | 3 | 5.5 | 2 | 5.9 | 0 | 0 | |
Luminal tumor type | |||||||||
Luminal A | 54 | 54 | 36 | 66.7 | 16 | 47.1 | 2 | 16.7 | 0.004 |
Luminal B | 46 | 46 | 18 | 33.3 | 18 | 52.9 | 10 | 83.3 | |
Estrogen receptor positivity percentage | |||||||||
ER ≥ 90% | 88 | 88 | 49 | 90.7 | 29 | 85.3 | 10 | 83.3 | 0.648 |
ER 30–80 | 12 | 12 | 5 | 9.3 | 5 | 14.7 | 2 | 16.7 | |
Progesterone receptor positivity percentage | |||||||||
PR ≥ 90% | 48 | 48 | 32 | 59.3 | 14 | 41.2 | 2 | 16.7 | 0.017 |
PR 0–85% | 52 | 52 | 22 | 40.7 | 20 | 58.8 | 10 | 83.3 | |
Treatment recommendation before RS assessment | |||||||||
Chemoendocrine recommendation | 46 | 46 | 18 | 33.3 | 17 | 50 | 11 | 91.7 | < 0.001 |
Endocrine only recommendation | 54 | 54 | 36 | 66.7 | 17 | 50 | 1 | 8.3 | |
Treatment recommendation after RS assessment | |||||||||
Chemoendocrine recommendation | 25 | 25 | 1 | 1.9 | 12 | 35.3 | 12 | 100 | < 0.001 |
Endocrine only recommendation | 75 | 75 | 53 | 98.1 | 22 | 64.7 | 0 | 0 | |
Type of hormonal treatment given | |||||||||
Tamoxifen | 58 | 58 | 36 | 66.7 | 17 | 50 | 5 | 41.7 | |
Aromatase inhibitors | 42 | 42 | 18 | 33.3 | 17 | 50 | 7 | 58.3 | |